AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read

FINCH LAWRENCE G sold $7.1M of MRAM

FINCH LAWRENCE G sold 268,130 shares of EVERSPIN TECHNOLOGIES INC. (MRAM) at an average of $26.40 ($26.40–$27.03, $7.08M total) across 2 trades on 2026-05-29.

Original reporting
SEC EDGAR · FINCH LAWRENCE G
Published Jun 2, 2026, 9:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MRAM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The insider sale could signal modest downside pressure, but the size relative to float is modest.

02

Market read

Primary relevance is to traders monitoring insider activity; broader market impact is limited.

03

What to watch

Potential upcoming dilution or secondary offerings could contextualize the insider's decision.

Relevance 6/10Novelty 6/10Timing: post-market filing

Background

SEC Form 4 filed by director Finch Lawrence G showing a $7.1M open‑market sale of EverSpin shares.

Market effects

Sector

Minimal impact on the broader semiconductor/MRAM sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale may reflect personal liquidity needs rather than confidence in the business.

Key entities

  • Company
    EverSpin Technologies Inc.

    Issuer of the disclosed insider transaction.

  • Insider
    Finch Lawrence G

    Director of EverSpin who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MRAM insider trading history →

Related articles

SEP 8
$MUMed

Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus

U.S. stock futures fell Sunday night after President Trump rejected Iran's peace proposal, raising concerns about global energy supplies. Dow, S&P 500, and Nasdaq futures declined, while oil prices rose. Micron (MU) and Sandisk (SNDK) shares surged over 5% due to high demand for memory chips. Everspin (MRAM) and MoonLake (MLTX) also saw significant gains.

stocktwits.com2 min
AUG 5
$MRAMMed

Everspin Reports Unaudited Second Quarter 2026 Financial Results

EVERSPIN TECHNOLOGIES INC. (MRAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Everspin Reports Unaudited Second Quarter 2026 Financial Results Chandler, AZ, August 5, 2026 —Everspin Technologies, Inc. (NASDAQ: MRAM), the world’s leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM) persistent memory solutions, toda

SEC EDGAR 8-K4 min
AUG 4
$MRAMMed

Everspin stock surges 14% on MaxLinear AI server partnership

Everspin Technologies (NASDAQ:MRAM) shares rose 14% and MaxLinear (NYSE:MXL) gained 9% after both firms announced an MOU to evaluate next-generation memory architectures for AI servers. The plan combines Everspin’s persistent low-latency MRAM with MaxLinear’s storage compression, encryption and acceleration platform, targeting data-intensive workloads and market development for cloud and enterprise customers.

investing.com3 min
MAY 24
$NVDAMedAI 9/10

MarketBeat Week in Review – 05/18 - 05/22

Stocks rose into the week’s close, with NVIDIA (NVDA) results and forward guidance cited as evidence of tangible demand for AI infrastructure. Retail stocks showed a mixed consumer backdrop amid inflation concerns. U.S. markets were closed Monday for Memorial Day. The review also highlighted items including SpaceX’s public S-1 filing and a Phase 2 Alzheimer’s trial miss at Biogen (BIIB).

finance.yahoo.com8 min